Accès gratuit
Numéro
Med Sci (Paris)
Volume 28, Numéro 4, Avril 2012
Page(s) 358 - 360
Section Nouvelles
DOI https://doi.org/10.1051/medsci/2012284008
Publié en ligne 25 avril 2012
  1. UNAIDS 2011, World AIDS Day Report. http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2216_WorldAIDS-day_report_2011_en.pdf.
  2. Munch J, Rucker E, Standker L, et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007 ; 131 : 1059–1071. [CrossRef] [PubMed]
  3. Roan NR, Munch J, Arhel N, et al. The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection. J Virol 2009 ; 83 : 73–80. [CrossRef] [PubMed]
  4. Roan NR, Sowinski S, Munch J, et al. Aminoquinoline surfen inhibits the action of SEVI (semen-derived enhancer of viral infection). J Biol Chem 2010 ; 285 : 1861–1869. [CrossRef] [PubMed]
  5. Roan NR, Muller JA, Liu H, et al. Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infection. Cell Host Microbe 2011 ; 10 : 541–550. [CrossRef] [PubMed]
  6. Olsen JS, Brown C, Capule CC, et al. Amyloid-binding small molecules efficiently block SEVI (semen-derived enhancer of virus infection)- and semen-mediated enhancement of HIV-1 infection. J Biol Chem 2010 ; 285 : 35488–35496. [CrossRef] [PubMed]
  7. Bouvet JP, Gresenguet G, Belec L. Vaginal pH neutralization by semen as a cofactor of HIV transmission. Clin Microbiol Infect 1997 ; 3 : 19–23. [CrossRef] [PubMed]
  8. Tevi-Benissan C, Belec L, Levy M, et al. In vivo semen-associated pH neutralization of cervicovaginal secretions. Clin Diagn Lab Immunol 1997 ; 4 : 367–374. [PubMed]
  9. Gupta K, Klasse PJ. How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked? PLoS Med 2006 ; 3 : e79. [CrossRef] [PubMed]
  10. McCormack S, Ramjee G, Kamali A, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (microbicides development programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010 ; 376 : 1329–1337. [CrossRef] [PubMed]
  11. Yoshida K, Yamasaki T, Yoshiike M, et al. Quantification of seminal plasma motility inhibitor/semenogelin in human seminal plasma. J Androl 2003 ; 24 : 878–884. [PubMed]
  12. Ronnberg L, Vihko P, Sajanti E, Vihko R. Clomiphene citrate administration to normogonadotropic subfertile men: blood hormone changes and activation of acid phosphatase in seminal fluid. Int J Androl 1981 ; 4 : 372–378. [CrossRef] [PubMed]
  13. Kim KA, Yolamanova M, Zirafi O, et al. Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI. Retrovirology 2010 ; 7 : 55. [CrossRef] [PubMed]
  14. Linke RP, Joswig R, Murphy CL, et al. Senile seminal vesicle amyloid is derived from semenogelin I. J Lab Clin Med 2005 ; 145 : 187–193. [CrossRef] [PubMed]
  15. Doncel GF. Exploiting common targets in human fertilization and HIV infection: development of novel contraceptive microbicides. Hum Reprod Update 2006 ; 12 : 103–117. [CrossRef] [PubMed]
  16. Sievers SA, Karanicolas J, Chang HW, et al. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature 2011 ; 475 : 96–100. [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.